全文获取类型
收费全文 | 50251篇 |
免费 | 3163篇 |
国内免费 | 245篇 |
专业分类
耳鼻咽喉 | 627篇 |
儿科学 | 1167篇 |
妇产科学 | 1216篇 |
基础医学 | 7031篇 |
口腔科学 | 1496篇 |
临床医学 | 5527篇 |
内科学 | 10734篇 |
皮肤病学 | 797篇 |
神经病学 | 4993篇 |
特种医学 | 1759篇 |
外科学 | 6282篇 |
综合类 | 323篇 |
一般理论 | 44篇 |
预防医学 | 3568篇 |
眼科学 | 803篇 |
药学 | 3434篇 |
1篇 | |
中国医学 | 59篇 |
肿瘤学 | 3798篇 |
出版年
2023年 | 298篇 |
2022年 | 255篇 |
2021年 | 1140篇 |
2020年 | 745篇 |
2019年 | 979篇 |
2018年 | 1194篇 |
2017年 | 1069篇 |
2016年 | 1254篇 |
2015年 | 1309篇 |
2014年 | 1738篇 |
2013年 | 2503篇 |
2012年 | 3789篇 |
2011年 | 3979篇 |
2010年 | 2365篇 |
2009年 | 2155篇 |
2008年 | 3287篇 |
2007年 | 3589篇 |
2006年 | 3202篇 |
2005年 | 3260篇 |
2004年 | 2998篇 |
2003年 | 2796篇 |
2002年 | 2565篇 |
2001年 | 425篇 |
2000年 | 348篇 |
1999年 | 479篇 |
1998年 | 561篇 |
1997年 | 459篇 |
1996年 | 407篇 |
1995年 | 346篇 |
1994年 | 304篇 |
1993年 | 308篇 |
1992年 | 234篇 |
1991年 | 228篇 |
1990年 | 208篇 |
1989年 | 217篇 |
1988年 | 195篇 |
1987年 | 169篇 |
1986年 | 172篇 |
1985年 | 209篇 |
1984年 | 180篇 |
1983年 | 163篇 |
1982年 | 190篇 |
1981年 | 158篇 |
1980年 | 137篇 |
1979年 | 111篇 |
1978年 | 121篇 |
1977年 | 129篇 |
1976年 | 94篇 |
1975年 | 106篇 |
1974年 | 80篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
55.
Lars von Knorring Béla G. L. Almay Jan Häggendal Folke Johansson Lars Oreland Lennart Wetterberg 《European archives of psychiatry and clinical neuroscience》1986,236(3):131-138
Summary The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating (a) chronic pain patients from healthy subjects, and (b) patients with idiopathic pain syndromes from patients with neurogenic pain syndromes. Separately each of the measures gave a significant but often low contribution to the discrimination, while a combination of several measures gave a complete discrimination both between healthy subjects and patients with chronic pain syndromes and between patients with idiopathic and neurogenic pain syndromes, respectively.Supported in part by grants from the Swedish Medical Research Council (grants no. 3371, 4145 and 5740) and by a grant from Stiftelsen Söderström-Königska Sjukhemmet 相似文献
56.
Hans D de Boer Jan van Egmond Jacques J Driessen Leo HD Booij 《Neuropsychiatric Disease and Treatment》2007,3(5):539-544
Steroidal neuromuscular blocking agents (NMBAs), such as rocuronium, are widely used in clinical anesthesia and emergency medicine to facilitate endotracheal intubation and artificial ventilation and to allow surgical access to body cavities. Reversal of neuromuscular blockade is important for the acceleration of patient recovery and prevention of postoperative residual neuromuscular blockade and reduces the incidence of severe morbidity and mortality associated with anesthesia management. Sugammadex is the first selective relaxant binding agent (SRBA) and has been designed to reverse the steroidal neuromuscular blocking drug rocuronium. Encapsulation of the rocuronium molecule by sugammadex results in a rapid decrease in free rocuronium in the plasma and subsequently at the nicotinic receptor at the motor endplate. After encapsulation, rocuronium is not available to bind to the nicotinic receptor in the neuromuscular junction. This promotes the liberation of acetylcholine receptors, and muscle activity reappears. This new concept of reversal of neuromuscular block induced by rocuronium (or vecuronium) led to impressive results in animal and phase 1 and 2 studies. Sugammadex is currently in phase 3 clinical studies and may be commercially available by 2008. 相似文献
57.
58.
Martine C M Willems L W Ernest van Heurn Geert W Schurink Frank M van der Sande Jan H M Tordoir 《Nephrology, dialysis, transplantation》2006,21(12):3583-3584
59.
Anthony M Dart Jan Erik Otterstad Bridget-Anne Kirwan John D Parker Sophie de Brouwer Philip A Poole-Wilson Jacobus Lubsen 《European journal of echocardiography》2007,8(4):275-283
AIMS: To evaluate the relationship between echocardiographic cardiac function and outcome in patients with stable symptomatic angina. METHODS: Baseline echo left ventricular ejection fraction and volume data measured in a central laboratory was available for 7016 patients (92% of the total) participating in the ACTION trial (A Coronary disease Trial Investigating Outcome with Nifedipine GITS). Ejection fraction was also measured by investigators. Evaluation of the different echocardiographic variables was based on adjusted hazard ratios comparing the unfavourable limit of the 90% range of the variable concerned to the favourable limit. RESULTS: The centrally measured ejection fraction was the most powerful predictor of all-cause death (adjusted hazard ratio=2.5), myocardial infarction, any stroke or transient ischaemic attack and overt heart failure (adjusted hazard ratio=4.5). The addition of either end systolic volume or end diastolic volume to ejection fraction did not materially affect the power of prediction. Compared to the central ejection fraction measurement, the investigator-measured ejection fraction was a less powerful predictor for all outcomes considered. CONCLUSION: Routine echocardiography carefully analysed by standardised methods provides useful prognostic information in patients with stable angina, including for total mortality. 相似文献
60.
Anja S Lindman Marit B Veier?d Jan I Pedersen Aage Tverdal Inger Nj?lstad Randi Selmer 《European journal of cardiovascular prevention and rehabilitation》2007,14(4):501-507
AIMS: To evaluate the predictive accuracy of the Systematic Coronary Risk Evaluation (SCORE) project high-risk function in Norway. METHODS AND RESULTS: We included 57 229 individuals screened in 1985-1992 from two population-based surveys in Norway (age groups 40-49, 50-59, and 60-69 years). The data have been linked to the Norwegian Cause of Death Registry. The SCORE high-risk algorithm for the prediction of 10-year cardiovascular disease (CVD) mortality was applied, and the risk factors entered into the model were age, sex, total cholesterol, systolic blood pressure, and smoking (yes/no). The number of expected events estimated by the SCORE model (E) was compared with the observed numbers (O). The SCORE low-risk algorithm was studied for comparison. In men, the observed number of CVD deaths was 718, compared with 1464 estimated by the SCORE high-risk function (O/E ratios 0.53, 0.53 and 0.45, for age groups 40-49, 50-59 and 60-69, respectively). In women, the observed and expected numbers were 226 and 547. The O/E ratios decreased with age (ratios 0.60, 0.45 and 0.37, respectively), i.e. the overestimation increased with age. The low-risk function predicted reasonably well for men (ratios 0.85, 0.92 and 0.79, respectively), whereas an overestimation was found for women aged 50-59 and 60-69 years (ratios 0.69 and 0.56, respectively). CONCLUSION: The SCORE high-risk model overestimated the number of CVD deaths in Norway. Before implementation in clinical practice, proper adjustments to national levels are required. 相似文献